Stryker Sets Trident Ceramic Hip Launch, Frets OP-1 Delay
This article was originally published in The Gray Sheet
Executive Summary
Stryker is planning a U.S. launch of the Trident ceramic-on-ceramic hip prosthesis in the second half of the year, the company says following receipt of an approvable letter from FDA.
You may also be interested in...
Stryker OP-1 Gains HDE Status For Failed Long-Bone Nonunion Fractures
Stryker plans to begin making its OP-1 (Osteogenic Protein 1) bone morphogenetic protein implant available in the U.S. by year-end under a humanitarian device exemption received from FDA Oct. 17, becoming the first company to have a BMP product reach the U.S. market.
Stryker OP-1 Gains HDE Status For Failed Long-Bone Nonunion Fractures
Stryker plans to begin making its OP-1 (Osteogenic Protein 1) bone morphogenetic protein implant available in the U.S. by year-end under a humanitarian device exemption received from FDA Oct. 17, becoming the first company to have a BMP product reach the U.S. market.
Stryker Will Discuss Rejected OP-1 PMA At Upcoming Meeting With FDA
Stryker expects to meet with FDA by March 1 to discuss the agency's "not approvable" letter for OP-1 bone growth factor for treating nonunion fractures.